Author: Cytospire

Cytospire Therapeutics Appoints Dr. Sumeet Ambarkhane as Chief Medical Officer

September 8, 2026
Cytospire Therapeutics announces oversubscribed £61 million ($83m) Series A financing to advance pipeline of first-in-class pan-gamma delta T cell engagers into clinical trials for the treatment of cancer

May 22, 2026

Cytospire Therapeutics Appoints Dr. Sumeet Ambarkhane as Chief Medical Officer